364 related articles for article (PubMed ID: 36105819)
1. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
2. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
3. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
4. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
5. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
6. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
7. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
9. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
10. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
Sheng G; Wang T; Gao Y; Wu H; Wu J
Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of comprehensive typing based on m6A and gene cluster in TNBC.
Wu H; Feng J; Wu J; Zhong W; Zouxu X; Huang W; Huang X; Yi J; Wang X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4367-4380. PubMed ID: 36109402
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer.
Sun X; Luo H; Han C; Zhang Y; Yan C
Front Oncol; 2021; 11():700062. PubMed ID: 34490098
[TBL] [Abstract][Full Text] [Related]
13. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
Front Immunol; 2022; 13():888650. PubMed ID: 35572541
[TBL] [Abstract][Full Text] [Related]
14. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
Wang Y; Peng L; Wang F
Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
16. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
Yang C; Yu T; Li Q; Xie F; Lin Q
Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
18. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
20. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]